Table 2.
Differential expression of SNHG16 promotor binding TFs and their correlation to the expression of SNHG16 in CRC clinical samples.
| Gene name | Gene id | Wnt targeta | FC(log2) | rs SNHG16 N + A + C | rs SNHG16 A + C | rs SNHG16 N |
|---|---|---|---|---|---|---|
| MYC | ENSG00000136997.10 | + | 2.1 | 0.8 | 0.4 | 0.4 |
| ASCL2 | ENSG00000183734.4 | + | 3.3 | 0.7 | 0.2 | 0.4 |
| ETS2 | ENSG00000157557.7 | + | 1.2 | 0.6 | 0.2 | 0.2 |
| MYBL2 | ENSG00000101057.11 | − | 1.6 | 0.6 | 0.03 | 0.4 |
| E2F7 | ENSG00000165891.11 | − | 0.8 | 0.6 | 0.1 | 0.3 |
| CEBPB | ENSG00000172216.4 | − | 1.4 | 0.6 | 0.02 | 0.2 |
| RARG | ENSG00000172819.12 | + | 0.9 | 0.5 | 0.05 | 0.4 |
| GMEB2 | ENSG00000101216.6 | − | 0.5 | 0.5 | 0.03 | 0.3 |
| ETV7 | ENSG00000010030.9 | − | 1.1 | 0.5 | 0.07 | 0.1 |
| RFX5 | ENSG00000143390.13 | − | 0.6 | 0.5 | 0.1 | 0.2 |
| SMC1A | ENSG00000072501.12 | − | 0.7 | 0.5 | 0.1 | 0.2 |
| TBX3 | ENSG00000135111.10 | + | 1.0 | 0.5 | 0.1 | 0.002 |
| TP73 | ENSG00000078900.9 | − | 0.6 | 0.5 | −0.05 | 0.2 |
| HOXA10 | ENSG00000253293.3 | + | 0.5 | 0.1 | −0.2 | 0.3 |
| E2F2 | ENSG00000007968.6 | − | −0.6 | −0.4 | −0.02 | 0.1 |
| FOXD2 | ENSG00000186564.5 | − | −0.8 | −0.4 | −0.01 | 0.1 |
| RXRA b | ENSG00000186350.8 | − | −0.6 | −0.5 | −0.2 | −0.4 |
| NR3C1 | ENSG00000113580.10 | − | −1.1 | −0.6 | −0.2 | 0.01 |
18/55 TFs binding to SNHG16 promotor on chromosome 17 position 72064795‐72066401 (Hg18) were significantly dysregulated in CRC clinical samples (FC(log2) >0.5 or < −0.5 with a Bonferroni corrected p‐value <0.001 (Student's unpaired t‐test)).
Genes that are significantly correlated to the expression of SNHG16 in adenomas/adenocarcinomas (A + C) are in bold (Spearman's ρ (rs) ≥ 0.2 or ≤ −0.2 and p < 0.05).
FC: fold change.
N: normal colon mucosa (n = 292).
A + C: adenoma + adenocarcinoma (n = 314).
a
Known Wnt target (direct/indirect).
b
Negative regulator of Wnt.